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association with migraine using logistic regression mod-
els. The GRS was significantly associated with migraine 
(OR = 1.56, p = 0.02) and migraine without aura (MWOA) 
(OR = 2.01, p = 0.003), but not with migraine with aura 
(MWA). The GRS was not associated with migraine fre-
quency, intensity or interference with daily activities. We 
show that a GRS combining multiple genetic risk variants 
is associated with MWOA but not MWA, suggesting a dif-
ferent genetic susceptibility background underlying the two 
forms of migraine.
Introduction
Migraine is a disabling disorder characterized by recur-
rent episodes of headache attacks and associated symp-
toms. With a lifetime prevalence of 18% in women and 6% 
in men, migraine is an extremely common disorder (GBD 
2015 Disease and Injury Incidence and Prevalence Collab-
orators 2016). Being ranked as the seventh most disabling 
disease in terms of years lived with disability, migraine has 
also a substantial socioeconomic impact (GBD 2015 Dis-
ease and Injury Incidence and Prevalence Collaborators 
2016).
Migraine without aura (MWOA) is the most common 
form of migraine and is characterized by recurrent severe 
headache attacks lasting 4–72 h with associated gastroin-
testinal and autonomic symptoms [Headache Classifica-
tion Committee of the International Headache Society 
(IHS) 2013; Headache Classification Subcommittee of the 
International Headache Society 2004]. Up to one-third of 
affected individuals experience transient focal neurological 
symptoms before or during the headache attack [(migraine 
with aura (MWA)] [Headache Classification Committee of 
the International Headache Society (IHS) 2013; Headache 
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Classification Subcommittee of the International Head-
ache 2004]. Although a number of hypotheses have been 
advanced, the pathogenesis of migraine is hitherto not 
fully understood, which is, however, of urgent need for the 
development of novel treatment approaches.
Migraine is thought to be the result of both genetic and 
environmental factors. The heritability of migraine has 
been estimated at 50% (Mulder et al. 2003) and has been 
suggested to be different for the two subtypes. While first-
degree relatives of patients with MWOA show a 1.9 times 
higher risk for MWOA and a 1.4 times higher risk for 
MWA, relatives of individuals with MWA have a 4 times 
higher risk to develop MWA while the risk to develop 
MWOA is not elevated (Silberstein and Dodick 2013). In 
recent years, several single-nucleotide polymorphisms 
(SNP) significantly associated with migraine have been 
identified (Anttila et al. 2010, 2013; Chasman et al. 2011, 
2014 Freilinger et al. 2012; Gormley et al. 2016). A recent 
meta-analysis pooling data from 29 genome-wide asso-
ciation studies (GWAS) identified 12 SNPs associated 
with increased migraine risk and, specifically, with larger 
effect sizes in MWOA compared to MWA cases (Anttila 
et al. 2013). However, other studies suggested an overlap 
between genetic variants associated with the two subtypes 
(Nyholt et al. 2015; Zhao et al. 2016).
The largest meta-analysis conducted so far on migraine 
genetics has just been recently published and included data 
of 59,674 migraine subjects and 316,078 controls. Besides 
the replication of some of the previously associated loci, 
this study identified 34 novel migraine-associated SNPs 
(Gormley et al. 2016). Notably, while this meta-analysis 
identified seven loci specifically associated with MWOA, a 
subset analysis revealed no significant association for MWA 
(Gormley et al. 2016). Therefore, the question to what 
extent a genetic heterogeneity exists between MWOA and 
MWA remains open. Importantly, all identified migraine-
associated SNPs show small effect sizes and account for a 
small part of migraine heritability (Gormley et al. 2016). 
Thus, the application of genetic risk score (GRS) analysis, 
which sums risk alleles across multiple genetic loci, may 
be of essential help to more efficiently explain the missing 
heritability of complex phenotypes, as seen in migraine. 
Recently, a GRS study suggested distinct genetic signatures 
for migraine with and without comorbid major depressive 
disorder (MDD) (Ligthart et al. 2014). Other studies inves-
tigated the genetic overlap between migraine and ischemic 
stroke (Malik et al. 2015) or coronary artery disease (Win-
svold et al. 2015), finding a much stronger overlap between 
cardiovascular diseases and MWOA rather than MWA.
Although first studies started to elucidate the isolated 
and combined effect of genetic variants on migraine risk, 
the aspect to what extent genetic susceptibility markers 
may predispose to a more severe form of migraine has only 
been scarcely investigated. To date, only one study tested 
the association between a cumulative GRS composed of 
seven SNPs and four proxies for severe migraine traits, 
i.e., early onset, >100 lifetime migraine attacks, prolonged 
migraine attacks and migraine chronification, in a clinical 
sample comprising 1806 migraine patients (Esserlind et al. 
2016). Two SNPs, rs2274316 (MEF2D) and rs11172113 
(LRP1), showed a significant association with high 
migraine attack frequency. However, the analysis evaluat-
ing the association between the GRS and “many lifetime 
attacks” or “prolonged migraine attacks” only showed a 
non-significant trend.
A cumulative genetic risk evaluation of migraine sub-
types, i.e., MWA and MWOA, and additional important 
aspects of migraine severity, including associated disabling 
symptoms, migraine intensity, and interference with daily 
activities under consideration of very recently detected 
novel migraine-associated variants would add further 
understanding to the genotype–phenotype interplay in 
migraine. To close this gap of knowledge, we investigated 
the association between genetic susceptibility factors, tak-
ing recently described, novel genetic susceptibility mark-
ers into consideration, and migraine prevalence and sever-
ity in a large population-based cohort. In the current study, 
we aimed to specifically evaluate if (1) a GRS based on 
migraine-associated SNPs is associated with migraine and 
migraine-type prevalence in this large population-based 
sample and if (2) the GRS is associated with migraine fre-
quency and distinct traits of migraine severity.
Methods
Sample
The present study included data from the CoLaus|PsyCoLaus 
study (Firmann et al. 2008; Preisig et al. 2009), a population-
based cohort study designed to investigate the genetic and 
environmental determinants of mental disorders and cardio-
vascular diseases (CVD) in the general population. Anthro-
pometric measures, DNA and plasma samples were collected 
from a total of 6733 individuals (CoLaus), aged between 35 
and 75 years, who were randomly selected between 2003 
and 2006 according to the civil register of the city of Laus-
anne (Firmann et al. 2008). Sixty-seven percent of the partic-
ipants of CoLaus in the age range of 35–66 years (N = 5535) 
also agreed to take part in the psychiatric evaluation (Psy-
CoLaus), resulting in a sample of 3719 individuals with 
both physical and psychiatric examination results (Preisig 
et al. 2009). The gender distribution of the PsyCoLaus sam-
ple (47% men) was similar compared to that of the general 
population in the same age range (Preisig et al. 2009). Scores 
on the General Health Questionnaire (GHQ-12) (Goldberg 
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1972), French translation (Bettschart and Bolognini 1996), 
a self-rating instrument completed at the somatic examina-
tion were similar for subjects who accepted to participate 
in PsyCoLaus and those who refused to participate. For the 
present analyses, we excluded 756 individuals because of 
missing genotyping data and 6 subjects because of missing 
lifetime MDD data, leaving a total of 2957 subjects. The 
CoLaus|PsyCoLaus was approved by the Institutional Ethics 
Committee of the University of Lausanne. Informed written 
consent was obtained from all participants.
Assessment of clinical and biological data
The lifetime prevalence of migraine was assessed accord-
ing to the criteria of the International Classification 
of Headache Disorders (ICHD-II), using the validated 
French version of the Diagnostic Interview for Headache 
Syndromes (DIHS). For all the participants who reported 
headache symptoms in the validated French translation 
(Leboyer et al. 1995) of the Diagnostic Interview for 
Genetic Studies (DIGS) (Nurnberger et al. 1994), these 
symptoms were examined in detail using the DIHS inter-
view. Subjects that satisfied the ICHD-II criteria were 
considered to be affected by migraine and were compared 
with subjects who did not meet the criteria o who did not 
report headache symptoms. The lifetime prevalence of 
MDD was assessed using the validated French transla-
tion (Leboyer et al. 1995) of the DIGS (Nurnberger et al. 
1994). The French translation of the DIGS revealed excel-
lent inter-rater reliability in terms of kappa and Yul’’s Y 
coefficients for major mood and psychotic disorders and a 
slightly lower 6-week test–retest reliability (Preisig et al. 
1999). Interviews were conducted by trained psycholo-
gists or psychiatrists and reviewed by an experienced 
senior psychologist. For each subject with a diagnosis 
of migraine, the following variables were extracted from 
the interview: age at onset, intensity of migraine (coded 
as a dichotomous variable comparing light/moderate 
versus severe migraine), migraine-associated gastrointes-
tinal symptoms (loss of appetite, hunger, nausea, vomit, 
diarrhea and abdominal pain), duration of the interval 
between two attacks, duration of the attack, and interfer-
ence with daily activities (evaluated with a score from 0 
to 100).
Genotyping
Nuclear DNA was extracted from whole blood of all par-
ticipants included in the CoLaus study. Genome-wide 
genotyping was performed using Affymetrix 500K SNP 
chips. Subjects were excluded from the analysis in case 
of inconsistency between sex and genetic data, a genotype 
call rate less than 90%, or inconsistencies of genotyping 
results in duplicate samples. Quality control for SNPs was 
performed using the following criteria: SNPs monomor-
phic among all samples; SNPs with call rates less than 95% 
deviation from the Hardy–Weinberg equilibrium (HWE) 
(p < 1 × 10E−07). Imputation was performed using mini-
mac (http://genome.sph.umich.edu/wiki/Minimac) and 
1000 Genomes (phase 1, version 3).
Fifty-four SNPs were chosen among previously genome-
wide determined, significant (p < 5 × 10E−08) migraine-
associated SNPs for which an odds ratio (OR) was reported 
by previous studies (Anttila et al. 2010, 2013; Freilinger 
et al. 2012; Gormley et al. 2016) (Supplementary Table 1). 
For 51 of these SNPs genotype data were available in our 
sample (Table 1). In case that an SNP was imputed, an 
imputation quality (r2−hat) >0.4 was set as threshold for 
the inclusion of the variant into further analyses.
Statistical analysis
Differences in continuous or categorical variables between 
subjects with migraine and controls were assessed 
using Mann–Whitney test or Pearson’s Chi-square test, 
respectively.
Table 1  Demographic and clinical characteristics of the sample (n = 2957)
Continuous variables are expressed as mean ± standard deviation; p values are calculated using Mann–Whitney test or Pearson’s Chi-square 
test, comparing subjects with migraine or migraine subtypes vs. controls
Significant differences are indicated in bold
MDD major depressive disorder, MWA migraine with aura, MWOA migraine without aura
Migraine vs. controls MWA vs. controls MWOA vs. con-
trols
Controls Migraine Statistics p MWA Statistics p MWOA Statistics p
N 2511 446 – – 152 – 294 –
Age (years) 51.7 (±8.9) 50.6 (±8.6) 519,856 0.016 51.1 (±9.0) 183,737 0.44 48.4 (±8.3) 336,119 0.012
Sex female (%) 50% 69% 55.27 <0.001 60% 5.34 0.02 74% 60.47 <0.001
Lifetime MDD (%) 41% 57% 41.47 <0.001 63% 29.45 <0.001 54% 19.09 <0.001
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Linkage disequilibrium (LD) between markers was 
measured by the r-squared coefficient using Haploview (v. 
4.2) (Barrett et al. 2005). SNPs with r2 values larger than 
0.8 were excluded. Deviation from HWE was tested using 
Chi-square test (p < 0.001). HWE p value threshold was 
corrected according to Bonferroni (p < 0.001, i.e., 0.05/51 
tested genetic variants). SNPs with a minor allele frequency 
(MAF) <0.01 were also excluded.
Genotypes for 51 out of 54 SNPs previously associ-
ated with migraine and for which an OR had been reported 
were available in our dataset (Supplementary Table 1). 
Two SNPs were not in HWE and were excluded. After the 
removal of SNPs with too low imputation quality (n = 0), 
with MAF <0.01 (n = 0) and of SNPs being in LD (n = 9), 
we proceeded with 40 SNPs in subsequent analyses.
The association between individual SNPs and migraine 
was tested using logistic regression analyses adjusting for 
age, sex and a lifetime diagnosis of MDD. A Bonferroni-
adjusted p value of 0.0013 (0.05/40) was applied.
Analyses were performed applying an additive genetic 
model. The genotype of each SNP was coded based on the 
amount of effect alleles, i.e., 0 for no effect alleles, 1 for 
heterozygous SNP carriers and 2 for individuals carrying 
two effect alleles. Subsequently, SNP-associated beta coef-
ficients were calculated based on the ORs reported in Ant-
tila et al. 2013, Freilinger et al. 2012 and Gormley et al. 
2016, and multiplied with the amount of alleles to obtain 
weighted SNP scores. A random forest model was con-
structed including weighted scores as predictors and a life-
time diagnosis of migraine as the target variable. The data-
set was randomly partitioned to a training (70%), validation 
(15%) and testing (15%) dataset to obtain a better unbiased 
estimate of error. A total of 10,000 random decision trees 
were created. SNPs with a positive mean decrease accuracy 
(i.e., variables that cause subjects to be incorrectly classi-
fied if removed) were considered to have a relevant influ-
ence on the model and were chosen for inclusion in the 
GRS.
GRS was calculated by summing up the weighted SNP 
scores according to the following formula:
with n the number of included SNPs in the model, and k the 
number of effect alleles. The load of effect alleles between 
subjects with migraine or migraine subtypes and controls 
was compared using the Mann–Whitney test.
The GRS was used as a continuous predictor in a binary 
logistic regression model with migraine (or migraine sub-
types) as the dependent variable, adjusting for age, sex, and 
a lifetime diagnosis of MDD. The GRS was also coded as 
a dichotomous variable to compare the association between 
n∑
i=1
k effect allelesSNPi × beta valueSNPi
migraine and the upper/lower quartiles of the GRS distribu-
tion using a binary logistic regression model.
In a second step, we ran a case-only analysis to test 
the association between the GRS and characteristics of 
migraine severity. Association between GRS and age at 
onset, migraine frequency, duration of attacks, or interfer-
ence with daily activities was tested performing Spear-
man’s correlation analyses, while the association between 
GRS and migraine intensity or gastrointestinal symptoms 
was tested with the Mann–Whitney test. To test the associa-
tion between the GRS and continuous or dichotomous clin-
ical characteristics of migraine, we constructed linear or 
logistic regression models, respectively, adjusting for age, 
sex and lifetime MDD. A p value <0.05 was considered 
significant. Analyses were performed using Haploview, the 
package Rattle (Graham 2011) in R (v. 3.2.3), SPSS v. 21 
(IBM, Armonk, NY, USA), and GraphPad Prism 5.
Results
Demographic and clinical characteristics of the sample
The demographic and clinical characteristics of the sample 
are shown in Table 1. Within the sample of 2957 partici-
pants, 446 subjects (15%) met the lifetime diagnostic cri-
teria for migraine. Among them, 34% fulfilled the criteria 
for MWA. Subjects with migraine were more likely to be 
younger, female, and to have a higher lifetime prevalence 
of MDD (Table 1). Therefore, analyses were adjusted for 
these variables.
Isolated SNPs have only a small impact on migraine 
risk
We first tested the association between migraine and the 40 
genetic variants individually in unadjusted analyses apply-
ing an additive genetic model and using logistic regression 
analysis (Supplementary Table 2).
Unadjusted analyses showed that two SNPs were asso-
ciated with migraine at a Bonferroni corrected threshold 
of 0.0013 (0.05/40): rs4814864, located in the SLC24A3 
gene (OR = 1.32, p = 0.0008), and rs186166891, located 
in the SUGCT gene (OR = 1.48, p = 0.0004). One genetic 
variant was associated with migraine at a nominal level 
(rs1024905, OR = 1.19, p = 0.016).
Subsequently, we applied a logistic regression analysis 
with migraine as the outcome variable, adjusting for age, 
sex, and a lifetime diagnosis of MDD. The association of 
rs186166891 with migraine was confirmed (OR = 1.54, 
p = 0.0002), while rs4814864 was associated with 
migraine only at a nominal level (OR = 1.30, p = 0.0017).
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The SNP rs186166891 was associated with MWOA 
(unadjusted OR = 1.58, p = 0.0004; adjusted OR: 1.66, 
p = 0.0001), but not with MWA (adjusted OR: 1.32, 
p = 0.15).
Analyses conducted in migraine subtypes also showed 
an association between rs1024905 and MWOA (unadjusted 
OR = 1.41, p = 0.0001; adjusted OR = 1.42, p = 0.0001), 
and a nominal association between rs4814864 and MWOA 
(unadjusted OR = 1.27, p = 0.017). Only one SNP was 
nominally associated with MWA (rs4814864, unadjusted 
OR = 1.41, p = 0.008; adjusted OR = 1.37, p = 0.015). 
None of the other variants was associated with migraine 
or migraine subtypes. These results pointed to a relatively 
small impact of single SNPs on migraine and migraine sub-
types in our population-based cohort.
A polygenic risk score composed of susceptibility SNPs 
for migraine is significantly associated with MWOA
To weight the genetic variants with regard to their impact 
on migraine outcome, a random forest algorithm was devel-
oped. As shown in Table 2 and Fig. 1, a total of 21 genetic 
variants (closest genes: MEF2D, PRDM16, TSPAN2, 
TRPM8, CARF, TGFBR2, PHACTR1, NOTCH4, SUGCT, 
DOCK4, PLCE1, HPSE2, ARMS2, MRVI1, LRP1, ITPK1, 
ZCCHC14, NLRP1, and SLC24A3) induced a positive 
mean decrease accuracy and were considered in the sub-
sequent calculation of the weighted GRS. The study par-
ticipants showed a GRS distribution ranging from −1.33 to 
0.76.
Mann–Whitney test showed that subjects with migraine 
or MWOA, but not MWA, had a higher load of risk alleles 
compared to controls (Fig. 2). As shown in Table 3, binary 
logistic regression analysis confirmed the significant 
impact of the GRS on the diagnosis of migraine. The covar-
iates female sex, younger age, and a lifetime diagnosis of 
MDD were also significantly associated with a diagnosis of 
migraine. 
Importantly, when stratifying migraine according 
to the main clinical subtypes MWA and MWOA, only 
MWOA appeared to be significantly impacted by the 
GRS (Table 3). When the GRS was dichotomized to com-
pare migraine prevalence between the bottom and top 
quartiles of the GRS distribution, the GRS was still asso-
ciated with migraine [OR: 1.45 (95% confidence inter-
val = 1.09–1.93), p = 0.011] and MWOA [OR: 1.76 (95% 
Table 2  SNPs previously associated with migraine and included in the GRS
a
 In the meta-analysis by Gormley et al. (2016), the association is reported for rs140002913 (now merged into rs9267918)
b
 The beta coefficients column shows natural logarithms of the ORs reported by previous studies
Chr chromosome, CI confidence interval, MA minor allele, MAF minor allele frequency, OR odds ratio, SNP single-nucleotide polymorphism
SNP Chr Location Gene MA MAF Reported OR (95% CI) Beta  coefficientb References
rs2274316 1 Genic MEF2D C 0.37 1.07 (1.04–1.09) 0.07 Anttila et al. 2013
rs10218452 1 Genic PRDM16 G 0.22 1.11 (1.10–1.13) 0.10 Gormley et al. 2016
rs2078371 1 Intergenic Near TSPAN2 C 0.12 1.11 (1.09–1.13) 0.10 Gormley et al. 2016
rs7577262 2 Genic TRPM8 A 0.10 0.87 (0.84–0.90) −0.14 Anttila et al. 2013
rs17862920 2 Genic TRPM8 T 0.10 0.77 (0.70–0.84) −0.26 Freilinger et al. 2012
rs10166942 2 Intergenic Near TRPM8 C 0.20 0.94 (0.89–0.99) −0.06 Gormley et al. 2016
rs138556413 2 Genic CARF T 0.03 0.88 (0.84–0.92) −0.13 Gormley et al. 2016
rs6790925 3 Intergenic Near TGFBR2 T 0.38 1.15 (1.10–1.21) 0.14 Anttila et al. 2013
rs9349379 6 Genic PHACTR1 G 0.41 0.93 (0.92–0.95) −0.07 Gormley et al. 2016
rs9267918a 6 Intergenic Near NOTCH4 A 0.06 0.91 (0.88–0.94) −0.09 Gormley et al. 2016
rs186166891 7 Genic SUGCT T 0.11 1.09 (1.07–1.12) 0.09 Gormley et al. 2016
rs10155855 7 Intergenic Near DOCK4 T 0.05 1.08 (1.05–1.12) 0.08 Gormley et al. 2016
rs10786156 10 Genic PLCE1 G 0.45 0.95 (0.94–0.96) −0.05 Gormley et al. 2016
rs12260159 10 Genic HPSE2 A 0.07 0.92 (0.89–0.94) −0.08 Gormley et al. 2016
rs2223089 10 Intergenic Near ARMS2 C 0.08 0.93 (0.91–0.95) −0.07 Gormley et al., 2016
rs4910165 11 Genic MRVI1 C 0.33 0.94 (0.91–0.98) −0.06 Gormley et al. 2016
rs11172113 12 Genic LRP1 C 0.42 0.90 (0.89–0.91) −0.11 Gormley et al. 2016
rs11624776 14 Intergenic Near ITPK1 C 0.31 0.96 (0.94–0.97) −0.04 Gormley et al. 2016
rs4081947 16 Intergenic Near ZCCHC14 G 0.34 1.03 (1.00–1.06) 0.03 Gormley et al. 2016
rs75213074 17 Intergenic Near NLRP1 T 0.03 0.89 (0.86–0.93) −0.12 Gormley et al. 2016
rs4814864 20 Genic SLC24A3 C 0.26 1.07 (1.06–1.09) 0.07 Gormley et al. 2016
1004 Hum Genet (2017) 136:999–1008
1 3
confidence interval = 1.24–2.50), p = 0.002] but not MWA 
(OR = 1.03, p = 0.89) in a regression logistic analysis 
adjusted for sex, age, and lifetime MDD.
Association between GRS and clinical characteristics 
of migraine
We evaluated furthermore to what extent the GRS was 
associated with clinical features characterizing migraine 
severity, including migraine intensity, associated gastro-
intestinal symptoms, age at onset, interference with daily 
activities, and migraine duration and frequency. As shown 
in Table 4, the GRS was not significantly associated with 
any of the tested variables in the whole sample or in 
migraine subtypes.
Discussion
The current study is, to our knowledge, the first to inves-
tigate the association between a polygenic risk score and 
migraine taking very recently described novel genetic sus-
ceptibility markers into account. Importantly, we inves-
tigate for the first time to what extent the developed GRS 
impacts the prevalence of migraine subtypes and migraine 
severity in a large population-based sample, adjusting 
for demographic and clinical confounders. We demon-
strate that the GRS based on SNPs previously identified 
in GWAS studies or meta-analyses to be associated with 
migraine specifically impacts MWOA, but not the risk for 
MWA. These findings allow the suggestion that MWOA 
and MWA have a different genetic susceptibility back-
ground that plays a role in their pathogenesis.
First-degree relatives of individuals with MWA show a 
considerably higher risk of MWA (4 times) compared to 
the higher risk of MWOA shown by first-degree relatives of 
MWOA patients (1.9 times) (Silberstein and Dodick 2013). 
On the basis of these estimates, the genetic contribution to 
migraine pathogenesis has been hypothesized to be higher 
for MWA compared to MWOA. However, a recent meta-
analysis of GWAS, including data from 23,285 migraine 
cases and 95,425 controls, failed to identify genetic variants 
significantly predisposing to MWA (Anttila et al. 2013). 
Since this meta-analysis only evaluated the association of 
common SNPs, a possible explanation for this inconsist-
ency lays in the fact that genetic predisposition to MWA 
could be mediated by rare variants with large effect size 
(Anttila et al. 2013). A recent reanalysis of the same data 
Fig. 1  Random forest model 
including 21 SNPs previously 
associated with migraine. The 
first 30 variables with the high-
est mean decrease accuracy are 
plotted. Twenty-one migraine-
associated SNP were shown 
to induce a positive change in 
mean decrease accuracy. These 
SNPs were thus considered to 
have a relevant influence on 
the model and were chosen 
for inclusion in the GRS. GRS 
genetic risk score, SNP single-
nucleotide polymorphism
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found significant heterogeneity of SNP effects between 
MWA and MWOA, although the direction of effect for 
the majority of selected SNPs was found to be the same 
between the two subtypes (Nyholt et al. 2015). The largest 
meta-analysis conducted so far, including data from 59,674 
affected subjects and 316,078 controls, also failed to iden-
tify SNPs associated with MWA (Gormley et al. 2016). Our 
results support the hypothesis that common variants with 
small effect sizes, even when evaluating them additively by 
GRS analysis, do not show an impact on MWA diagnosis.
Among the new susceptibility loci identified by Gorm-
ley et al. (Gormley et al. 2016) and included in our GRS, 
two lie in or near genes involved in regulation of vascu-
lar tone (MEF2D, DOCK4, and SLC24A3) (Dong et al. 
2006; Firulli et al. 1996; Kang et al. 2015), while ARMS2, 
PHACTR1, TGFBR2, LRP1, and NOTCH4 have been pre-
viously associated with vascular disease (Delev et al. 2017; 
Beaudoin et al. 2015; Guo et al. 2016; Hayashi et al. 2010; 
Yang et al. 2016), consistently with the suggested role of 
vascular dysfunction in migraine pathogenesis. Interest-
ingly, one of the novel migraine-associated SNPs included 
in our GRS, rs75213074, is located near NLRP1, which 
encodes for the sensor component of an inflammasome (a 
protein complex that activates caspases and cytokines in 
response to damage-associated signals) (Guo et al. 2015). 
As outlined by a recent review, due to their ability to inte-
grate various inflammatory signals and their expression in 
endothelial cells, neurons, and astrocytes, inflammasomes 
represent a promising functional link between vascular and 
neurological diseases (Lenart et al. 2016).
Similarly to other complex phenotypes, migraine herit-
ability appears to be due to a large number of weak associa-
tions with many genetic variants, rather than few common 
risk variants (Anttila et al. 2013; Chasman et al. 2016). 
Therefore, a GRS evaluating the cumulative effect of multi-
ple variants with a small impact is more likely to be able to 
explain a part of migraine missing heritability.
To date, only a few studies evaluated the association 
between a GRS and migraine prevalence in a population-
based sample. Rodriguez-Acevedo and coworkers found 
an association between migraine and a GRS (includ-
ing 51 genetic variants previously nominally associated 
with migraine) in a small sample including 74 cases and 
211 controls (Rodriguez-Acevedo et al. 2015). We used a 
different approach by selecting only genetic variants pre-
viously associated with migraine with a genome-wide 
significant threshold for which an OR had been reported 
and we further prioritized variables using a random forest 
algorithm. Another study investigated the overlap between 
migraine and MDD, showing that the subgroup of patients 
with migraine and comorbid MDD are genetically most 
Fig. 2  Box and whisker plot of GRS in subjects with migraine or 
migraine subtypes compared to controls. Mann–Whitney test showed 
a significant association between the genetic risk score and migraine 
(U = 522,400, p = 0.02) or MWOA (U = 329,900, p = 0.003), but 
not the MWA subtype (U = 189,200, p = 0.8). * <0.05, ** <0.005. 
GRS genetic risk score, MWA migraine with aura, MWOA migraine 
without aura
Table 3  Association between 
GRS and diagnosis of migraine 
and migraine subtypes 
according to logistic regression 
models
Significant differences are indicated in bold
CI confidence interval, GRS genetic risk score, MDD major depressive disorder, MWA migraine with aura, 
MWOA migraine without aura, OR odds ratio
Migraine (N = 446) MWA (N = 152) MWOA (N = 294)
vs. controls (2511)
OR (95% CI) p OR (95% CI) p OR (95% CI) p
GRS 1.56 (1.07–2.27) 0.020 0.96 (0.54–1.72) 0.890 2.01 (1.28–3.17) 0.003
Female sex 2.04 (1.63–2.55) <0.001 1.22 (0.86–1.72) 0.260 2.73 (2.06–3.61) <0.001
Age 0.99 (0.97–1.00) 0.010 1.00 (0.98–1.01) 0.590 0.98 (0.97–0.99) 0.004
MDD 1.63 (1.32–2.01) <0.001 2.37 (1.67–3.36) <0.001 1.34 (1.04–1.72) 0.023
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similar to MDD patients (Ligthart et al. 2014). On the basis 
of these results, it was suggested that migraine with and 
without underlying MDD might have different genetic sub-
strates (Ligthart et al. 2014).
In our study, a large percentage of subjects with 
migraine showed underlying MDD, with subjects with 
MWA presenting a higher risk (OR = 2.36) compared with 
the MWOA subtype (OR = 1.35). It cannot be excluded 
that the specificity of our GRS for MWOA could be partly 
due to the lower prevalence of MDD in this subsample. It 
is possible that genetic variants with an overlapping impact 
on both migraine and MDD risk might exert a higher 
impact on the MWA subtype.
Only one study evaluated the association between a 
GRS and proxies of migraine severity in a clinical sample 
(Esserlind et al. 2016). The authors reported that a poly-
genic risk score including 12 loci was not associated with 
early onset, frequency, duration of attacks, and tendency to 
chronification. Our results confirm and extend these find-
ings reporting no association between a GRS and other 
characteristics of migraine severity, such as migraine inten-
sity, gastrointestinal-associated symptoms, or interference 
with daily activities.
Our results must be interpreted in light of their limita-
tions. Our study was not powered enough to investigate 
the association between migraine and rare genetic variants, 
which might especially play a role in MWA. Since avail-
able studies, including the largest meta-analysis conducted 
to date (Gormley et al. 2016), have not been able to iden-
tify genetic variants significantly associated with MWA, 
further studies characterized by larger sample size and 
powered enough to identify rare genetic variants could be 
of help to construct a GRS that could prove to be more spe-
cific for MWA. However, it cannot be excluded that genet-
ics might play a minor role in MWA pathogenesis and that 
other molecular biological mechanisms (e.g., methylation) 
may be of stronger relevance for MWA. Moreover, our 
study included a lower number of participants with MWA 
compared to MWOA, which could have limited our statisti-
cal power to identify a significant association between the 
GRS and this subtype. Future studies including a balanced 
number of participants with MWOA and MWA are needed 
to confirm our findings. Finally, for all the participants the 
interviews were conducted by trained psychologists or psy-
chiatrists and reviewed by an experienced senior psycholo-
gist, but not by headache specialists.
Conclusion
In conclusion, the present study suggests that a GRS com-
bining the effect of multiple loci is associated with MWOA Ta
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but not MWA in a large population-based sample. Genetic 
risk variants so far detected to play a role in migraine are 
not able to explain a comprehensive set of clinical charac-
teristics of migraine severity.
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